Nearly all patients with chronic hepatitis C virus (HCV) infections should receive direct-acting anti-viral agents, according to updated guidelines by the American Association for the Study for Liver Diseases and the Infectious Diseases Society of America.
Empiric beta-lactam and macrolide monotherapy are similarly effective in outpatient management of children with community-acquired pneumonia (CAP), according to results of a multicenter retrospective study in 1164 children treated for CAP at primary care pediatric clinics in Pennsylvania.
A large international study, published in Nature Genetics, found that the H58 “superbug” version, which is resistant to multiple types of antibiotics, is now a major global health threat affecting many countries, including Asia and Africa, where typhoid is endemic.
The number of antibiotic-resistant strains continues to rise rapidly. Statistics from the Centers for Disease Control and Prevention (CDC) and the Infectious Diseases Society of America (IDSA) point to alarming trends that are exacerbated by fewer new antibiotics coming into the market and high costs.
Patients with advanced liver disease or other severe symptoms of hepatitis C virus (HCV) infection should be first in line for drug therapy, according to a new guideline from the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America.
It has been more than a decade since the clinical battle began with community-acquired methicillin-resistant Staphylococcus aureus (MRSA), and physicians are still trying to figure out how to diagnose, treat, and prevent this virulent form of staph infection, which is immune to many antibiotics.
Investigators compared outcomes in hospitalized children with community-acquired pneumonia who were treated with a narrow-spectrum antibiotic (ampicillin/penicillin) versus a broad-spectrum agent (ceftriaxone/cefotaxime), each by a parenteral route.
Although little difference exists in outcomes between broad-spectrum and narrow-spectrum antibiotics for children hospitalized with community-acquired pneumonia (CAP), narrow-spectrum agents are associated with a shorter hospital stay, according to a recent study, and, not incidentally, help to minimize the problem of antibiotic resistance.